Although molecular imaging has had a dramatic impact on diagnostic imaging, it has only recently begun to be integrated into interventional procedures. Its significant impact is attributed to its ability to provide noninvasive, physiologic information that supplements conventional morphologic imaging. The four major interventional opportunities for molecular imaging are, first, to provide guidance to localize a target; second, to provide tissue analysis to confirm that the target has been reached; third, to provide in-room, posttherapy assessment; and fourth, to deliver targeted therapeutics. With improved understanding and application of 18 F-FDG, as well as the addition of new molecular probes beyond 18 F-FDG, the future holds significant promise for the expansion of molecular imaging into the realm of interventional procedures.
With the advent of each new diagnostic imaging tool-from radiography to ultrasound to CT to MRI-interventionalists have been able to incorporate the added modality into their practice, leveraging its advantages and advancing the field of image-guided intervention (1, 2) . It is therefore not surprising that molecular imaging is finding its way into the interventionalist's armamentarium.
Although molecular imaging has had a dramatic impact on diagnostic imaging (3) , it has only recently begun to be integrated into interventional procedures. Its significant impact is attributed to its ability to provide noninvasive, physiologic information that supplements conventional morphologic imaging (4) . With improved understanding and application of 18 F-FDG, as well as the addition of new molecular probes beyond 18 F-FDG, the future holds significant promise for the expansion of molecular imaging into the realm of interventional procedures (5) .
Molecular imaging probes are based on radioisotopes, fluorescence, or combinations of these (4) . Because most interventional radiology procedures are imaged extracorporeally and most fluorescent probes have only a limited depth of penetration (6) , the field of molecular imaging for interventional radiologists currently is based mostly on molecular probes using radioisotopes, usually 18 F-FDG PET (7) . In the future, as integration of PET scanners and optical imaging scopes takes place, use of combination molecular probes may become more common (8) .
With the advantages of having high specificity and providing physiologic information, especially when coupled with anatomic imaging such as in PET/CT, molecular imaging has become an invaluable tool for the interventionalist. The four major interventional opportunities for molecular imaging are, first, to provide guidance to localize a target; second, to provide tissue analysis to confirm that the target has been reached; third, to provide in-room, posttherapy assessment; and fourth, to deliver targeted therapeutics. This article will provide an update on the status of interventional molecular imaging.
FUSION OF PREVIOUS IMAGES WITH PROCEDURAL IMAGES
Previously acquired PET images can be fused or registered with intraprocedural CT or ultrasound images to integrate the physiologic information from 18 F-FDG PET with the detailed anatomic information from the cross-sectional techniques (9) . The usefulness of this multimodality fusion has been demonstrated for both image-guided biopsies and tumor ablations (10, 11) . However, this technique is limited by the need to use previously obtained PET images and the difficulty of registration (12) .
Challenges to registering previously acquired images with procedural images include differences in patient positioning between the previous imaging session and the procedural imaging session (e.g., procedures may be performed with the patient prone, lateral, or oblique), differences in respiration, differences in arm positioning, and differences resulting from instruments pushing tissue during a procedure (13) . These challenges have led some to perform PET-guided procedures within a PET/CT suite, where improved registration is possible (13, 14) .
DEDICATED INTERVENTIONAL PET/CT SCANNERS
A dedicated interventional PET/CT scanner would be ideal to avoid several of the image registration issues. With such a scanner, the position of the patient during the procedural PET scan would be identical to that during the procedural CT scan. With assistance from the anesthesia team, registration issues stemming from respiratory motion may be reduced (13) . Although continuous breathing during diagnostic PET acquisitions may distort lesion size or shape or create partial-volume effects, particularly along the direction of maximal respiratory motion, registration may be improved through the use of breath-holding techniques, sedation, or general anesthesia during the procedure (15, 16) . The use of short-breath-hold PET acquisitions (e.g., 20 s) has been shown valuable (13) . Also, performing a procedure within the PET scanner allows updating of the PET data at different time points in response to procedure-related changes.
INTERVENTION-CUSTOMIZED ACQUISITION PROTOCOLS
Although diagnostic imaging is focused on obtaining the highestquality images, interventional imaging is focused much more on rapidly obtaining the information needed to perform the procedure at hand (13) . Because patients always have a diagnostic-quality study available for planning, the interventional imaging can be of lower quality and tailored to meet the needs of the procedure. For example, interventional PET/CT is usually performed on only one or two focused bed positions rather than on the whole body. Instead of using the standard 444-MBq 18 F-FDG dose that is applied for diagnostic studies, in our practice we use about 222 MBq to guide biopsies and about 148 MBq to guide ablations. The 18 F-FDG uptake times are usually quite variable and depend on the patient preparation and positioning times. In our experience, the uptake times have ranged from 45 to 160 min. Even with extended uptake times, imaging of sufficient quality has been achieved (17) . The PET acquisition times are usually lowered to the length of a single breath hold, which may be 20 s (13) . If general anesthesia and paralysis are used, 90-s acquisition times with respiratory suspension can be applied to increase image quality and improve registration (15) .
During PET/CT-guided interventions, a PET image acquired at the start of the procedure can rapidly be fused with multiple series of CT images acquired as the needle advances toward the target. PET imaging can also be repeated to confirm that the target has been reached.
When the split-dose technique is used to assess an interventional treatment such as an ablation, an initial 148-MBq 18 F-FDG dose is used to guide the needle and a second dose of about 222 MBq is used after ablation to assess the completeness of treatment ( Fig. 1) (14) . The uptake time allowed after the second dose is approximately 30 min rather than the 60 min usually allowed for diagnostic PET/CT. All these protocol modifications emphasize the differing priorities of interventional versus diagnostic imaging.
THE INTERVENTIONAL PET/CT ROOM
Performing interventions within a PET/CT scanner is both feasible and valuable (7) and can be made more practical through certain modifications (15) . These include CT fluoroscopy, an in-room image display, an anesthesia boom with gases, and a system to communicate between the control room and the procedure room. A scanner with a large bore (.70 cm) to accommodate the patient plus a partially extending needle is critical.
CLINICAL APPLICATIONS

Guidance of Biopsy
Targeted percutaneous biopsies are commonly performed under CT and ultrasound guidance to obtain a definitive tissue diagnosis. For 18 F-FDGavid lesions, PET/CT guidance has been shown to enable targeting of lesions that are not well visualized with CT or other imaging methods ( Fig. 2) (18) . A particular advantage of 18 F-FDG PET/CT guidance is the ability to differentiate and selectively sample the most metabolically active component of a heterogeneous lesion (19) . This capability may reduce false-negative results and improve disease stratification (20) . For example, it is known that hypermetabolic, 18 F-FDG-avid regions within neurofibromas may be areas of malignant transformation (21) . It is important, therefore, that these hypermetabolic areas be targeted for biopsy. Biopsy is commonly used to detect cancer recurrence after surgery, radiation therapy, or ablation. When based simply on anatomic images, such biopsies can be especially confounded by prior treatment. PET/CT can guide the biopsy to the metabolically active area in a previously treated zone (22) . Another advantage of PET/CT is that it may be able to demonstrate abnormalities not visible on anatomic images. Performing these procedures in a PET/CT suite permits confirmation of reaching the target.
Validation of New Molecular Tracers
As new PET tracers beyond 18 F-FDG are developed to leverage increased target specificity, their imaging findings need pathologic validation by PET/CT-guided biopsy. For example, guided biopsy of PETpositive sites has been used to confirm the sensitivity and specificity of two tracers of prostate-specific membrane antigen: the monoclonal antibody tracer 89 (25) .
Confirmation of Biopsy Adequacy
To be certain that a needle-biopsy specimen contains sufficient tissue to allow for a diagnosis, a pathologist is frequently asked to make an on-site evaluation. For 18 F-FDG-avid lesions, such a determination may be possible with an on-site autoradiography device (26) . Fanchon et al. found that on-site autoradiographic measurement of a biopsy specimen could determine the probability that it would be positive for cancer (26) . This type of system might be applicable when there is no PET scanner to guide the intervention; with injection of a known level of radioactivity, the likelihood of appropriate biopsy targeting can be determined even without a PET scanner simply by measuring for the presence of a threshold level of radioactivity. Similar systems that use fluorescent molecular probes have also been applied to analyze biopsy specimens for adequacy (6).
Assessment of Treatment
Several studies have shown the value of imaging for detecting recurrence of tumor several months after ablation (5). However, early detection of recurrence with 18 F-FDG PET has been confounded by 18 F-FDG uptake related to inflammation and posttherapy changes (27) . The novel use of 18 F-FDG PET immediately after an ablation, while the patient is still on the interventional table, offers an opportunity to detect viable cells before inflammation begins and to administer additional treatment before the end of the procedure.
In one approach, dubbed the split-dose technique (14) , the standard 444-MBq 18 F-FDG dose for diagnostic PET/CT is split into two doses. The first dose, 148 MBq, is administered before the procedure to guide placement of the ablation probes. The second dose, 296 MBq, is given after the ablation to assess for viability. Although the first dose remains trapped in the ablated cells (28) , it has decayed significantly by the time the second dose is given. The ratio of the initial 18 F-FDG in the patient (i.e., the background radioactivity) to the new 18 F-FDG is approximately 1:7. We have used this ratio to assess for areas of viable cancer after ablation of liver tumors. To normalize ablation-zone uptake for background uptake, we calculate the tissue radioactivity concentration (TRC) ratio as follows: TRC ratio 5 [(lesion TRC max -liver TRC mean )/ lesion TRC max ] · 100. In one series of patients from our institution, a positive predictive value of 100% was found by calculating the TRC in the treatment zone (TRC ratio . 28.3) (Fig. 3) . The sensitivity of this method of detecting residual disease immediately after ablation is better than that of contrast-enhanced CT. It is hoped that this use of molecular imaging to assess and improve an interventional treatment before the end of the procedure will lead to improved outcomes.
RADIOTRACER CHALLENGES
Although the use of 18 F-FDG has enabled exploration of interventional applications of molecular imaging, 18 F-FDG has limitations due to its biodistribution and half-life (15) . The 110-min half-life of 18 F means that treatment can be effectively assessed only once during a procedure. The split-dose approach with a long procedure time allows for a potential second dose. However, a tracer with a shorter half-life (such as 11 C) would be more ideal, as it would allow for multiple doses and assessments throughout the treatment procedure without the confounding effect of remaining activity from earlier doses (29) .
RADIATION EXPOSURE
Interventionalists must be aware that the factors governing radiation exposure in PET/CT are different from those most familiar to interventional radiologists (15) . In fluoroscopy-or CT-guided procedures, the operator controls the radiation dose directly by controlling the x-ray source and can limit the exposure time; increase the distance from the patient, when feasible; use low-dose, collimation, and antiscatter techniques; and wear protective devices such as shields. Because the source of the radiation is the patient, and because the photon energy of PET is 511 keV higher than the typical x-ray photon energy of fluoroscopy (70-120 keV), personal protective devices are relatively ineffective against PET radiation.
However, the dose to the operator from PET/CT-guided procedures is not significantly different from typical doses from fluoroscopically guided procedures (30). Ryan et al. (30) showed that the median effective dose during an ablation in which 444 MBq of 18 F-FDG were injected was 0.02 mSv (range, 0-0.13 mSv) for the primary operator, 0.01 mSv (range, 0-0.05 mSv) for the nurse anesthetist, and 0.02 mSv (range, 0-0.05 mSv) for the radiology technologist. The median extremity-dose equivalent for the operator was 0.05 mSv (range, 0-0.62 mSv). Although the median dose from PET/CTguided procedures remained within an acceptable range for an interventional radiologist, the range of doses in this study was varied and had a maximum of 0.13 mSv, which is higher than the median dose by a factor of 6.5. In the study of Ryan et al., the exposure from 444-MBq dosing correlated with procedure duration and with type of imaging guidance. The median effective dose to the operator from the procedure was 0.015 mSv with conventional biopsy-mode CT imaging guidance, compared with 0.06 mSv with in-room imaging guidance, although the small sample size prevented this difference from achieving statistical significance (P 5 0.06). Therefore, the major determinant of radiation exposure to the operator from PET/CT-guided interventional procedures is time spent near the patient. Given the reasonable range of exposures seen, the perception of increased radiation dose to operator and staff should not limit the expansion of PET/CT as a tool to guide intervention. Rather, different methods of minimizing radiation exposure should be emphasized during PET-guided intervention. In our practice, we have lowered the dose to 222 MBq for biopsy and 148 MBq for needle placement during ablation-reductions that should markedly decrease the radiation exposure of staff. In the splitdose technique, the operator is generally not closely exposed to radiation during injection of the second dose or during its uptake time.
FLUORESCENT IMAGING
Fluorescent probes have the benefit of not using ionizing radiation, but they have a limited depth of penetration (31) . The application of fluorescent probes has thus been confined to optical imaging scopes that can directly visualize tissue. In one such application, the scope is passed through an introducer cannula during a biopsy, with the appearance of indocyanine green fluorescence confirming that the target has been reached. The importance of this type of molecular imaging will increase as it begins to play a larger role in interventional radiology (6) .
DELIVERY OF MOLECULAR THERAPEUTICS
Interventionalists perform endovascular oncologic procedures to deliver lethal payloads directly to the vascular supply feeding cancers, thereby minimizing systemic exposure to these toxic therapeutics. Applying similar principles, Kratochwil et al. have been delivering molecularly targeted therapeutic agents to cancers (32) . Relying on the increased vascularity and increased somatostatin receptor expression of neuroendocrine tumors, this group has been delivering a-radionuclides ( 213 Bi-DOTATOC) and b-radionuclides ( 90 Y-or 177 Lu-DOTATOC) with good clinical effect and limited toxicity (33) .
COST-EFFECTIVENESS
Just as with every new technology, be it diagnostic PET/MR, optical cameras, or interventional PET/CT, cost and value need to be addressed. Dedicating a PET/CT scanner to interventional applications has been shown to have the value of allowing biopsies of targets not visualized on conventional imaging. Similarly, the possible cost value of interventional PET/CT, such as through an improvement in ablation outcomes or a reduction in the number of ablations that need to be repeated because of incomplete treatment, needs to be more formally studied.
CONCLUSION
As the role of molecular imaging in cancer diagnosis increases, the role in interventional oncology will expand as well. The physiologic information afforded by molecular imaging adds value to and complements the information provided by anatomic imaging. The ability to distinguish viable from nonviable tumors and to identify particular foci of cancer amid tumor heterogeneity are critical benefits of molecular tracers. Of the four major interventional opportunities for molecular imaging-to guide toward a target, confirm that it has been reached, assess treatment, and deliver targeted therapeutics-value for target localization and treatment assessment has already been demonstrated. Procedure protocols that leverage prior diagnostic studies permit modified, interventionally favorable techniques. However, additional work to improve hardware, tracers, and logistics is still needed. Like other imaging tools that were initially thought valuable for diagnosis and later became so for interventional procedures as well, molecular imaging clearly will become a critical adjunct in interventions.
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